Pradaxa

If you, a family member, or loved one have taken the medication Pradaxa and suffered from uncontrolled and/or excessive bleeding, heart attack, or experienced other serious or fatal side effects, you might be entitled to compensation.

Pradaxa (dabigatran) is a blood-thinning medicine approved by the U.S. Federal Drug Administration (FDA) in October 2010 and manufactured by Boehringer Ingelheim Pharmaceuticals Inc. The drug is marketed for stroke prevention associated with atrial fibrillation. People who have atrial fibrillation have occasional "fluttering" in the heart, which increases the risk that blood will pool in the heart, form a clot, and be pumped into the brain (causing stroke).

Pradaxa reduces the risk of strokes by inhibiting thrombin, an enzyme that is necessary for the formation of blood clots. Pradaxa was developed as an alternative to Warfarin and is widely prescribed for off label use as a "new generation" of anti-coagulant medication. However, Warfarin is inactivated by many foods containing Vitamin K and in an emergency, doctors can administer a simple dose of Vitamin K, which allows blood to clot and prevents bleeding to death.

In contrast, when a Pradaxa patient needs emergency treatment, they must undergo dialysis to mechanically remove Pradaxa from the bloodstream. This can take several hours. By the time dialysis takes effect, a person can bleed to death — even from a minor injury. As a result, the FDA is evaluating reports of serious or even fatal bleeding events in patients taking Pradaxa. In 2011, manufacturer Boehringer Ingelheim admitted to knowledge of cases of fatal bleeding yet they continue to market the drug.

Now, Pradaxa warns of side effects of bleeding which can lead to death, as well as:

  • Lethargy
  • Blood in urine
  • Red/black tarry stool
  • Headache
  • Nosebleed
  • Vomiting
  • Dizziness
  • Unusual bruising
  • Brain bleed
  • Stroke or Heart Attack

Contact Us Today

I have read and agree to the disclaimer.

Send My Information